Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Pharma channel feed
Eisai cuts Leqembi 2027 sales forecast by half but expects 'continued growth'
2 months ago
Senate committee backs Dr. Oz's nomination to lead CMS
2 months ago
People
Axsome reports Phase 3 win for Sunosi in adults with ADHD, with a high-dose caveat
2 months ago
R&D
GSK scores FDA approval for antibiotic to treat uncomplicated UTIs
2 months ago
FDA+
Merck strikes deal for heart drug, worth up to $2B, with China’s Hengrui
2 months ago
Deals
China
Three major questions on pharma tariffs Trump claims are on the way
2 months ago
Manufacturing
AbbVie files trade secrets suit against ADC competitor
2 months ago
Law
Liver cancer drug combo gets second FDA rejection over manufacturing issues
2 months ago
FDA+
Manufacturing
Trump think tank resurrects international drug pricing model to go after 'global freeloading'
2 months ago
Law
Alnylam hopes its broad ATTR-CM label can give Amvuttra an edge in heart disease
2 months ago
FDA+
BARDA cancels annual biomedical event for industry, government reps
2 months ago
FDA+
The buildup to Chimerix's $935M exit to Jazz, with more than half a dozen parties intrigued
2 months ago
Deals
FDA approves Novartis’ Fabhalta in another rare kidney disease
2 months ago
FDA+
AstraZeneca broadens presence in China, promising $8B+ to Harbour and Syneron
2 months ago
Deals
China
Johnson & Johnson earmarks $55B to boost US capacity
2 months ago
Manufacturing
Updated: FDA approves Alnylam’s Amvuttra in ATTR-CM, kicking off competition with Pfizer, BridgeBio
2 months ago
FDA+
CDC vaccine meeting, delayed earlier this year, is rescheduled
2 months ago
R&D
Akero exec calls FDA's accelerated approval guidance for MASH drugs 'bizarre'
2 months ago
R&D
FDA+
Novo Nordisk says new early R&D structure will ‘future-proof’ its business
2 months ago
Paratek boosts commercial portfolio in move to buy Optinose and its nasal spray
2 months ago
Deals
Novartis touts Zolgensma data in older kids as it readies regulatory filings
2 months ago
Gilead stock slips as HHS denies reports of HIV funding cuts
2 months ago
Law
Ahead of FDA decision, Alnylam faces the big question: Can it make money?
2 months ago
FDA+
In Focus
Pfizer fully exits Sensodyne maker Haleon in $3.3B stake sale
2 months ago
First page
Previous page
8
9
10
11
12
13
14
Next page
Last page